Premium
Early or deferred initiation of efavirenz during rifampicin‐based TB therapy has no significant effect on CYP3A induction in TB‐HIV infected patients
Author(s) -
Aklillu Eleni,
Zumla Alimuddin,
Habtewold Abiy,
Amogne Wondwossen,
Makonnen Eyasu,
Yimer Getnet,
Burhenne Jürgen,
Diczfalusy Ulf
Publication year - 2021
Publication title -
british journal of pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.432
H-Index - 211
eISSN - 1476-5381
pISSN - 0007-1188
DOI - 10.1111/bph.15309
Subject(s) - efavirenz , rifampicin , medicine , pharmacology , cyp3a , cohort , gastroenterology , human immunodeficiency virus (hiv) , tuberculosis , immunology , antiretroviral therapy , viral load , pathology , cytochrome p450 , metabolism
In TB-HIV co-infection, prompt initiation of TB therapy is recommended but anti-retroviral treatment (ART) is often delayed due to potential drug-drug interactions between rifampicin and efavirenz. In a longitudinal cohort study, we evaluated the effects of efavirenz/rifampicin co-treatment and time of ART initiation on CYP3A induction.